Arbutus Biopharma Corporation Stock Earnings Report NASDAQ:ABUS
Current P/E ratio: -4.70 | Price (Jan 19, 2022, EOD): $3.01 (Find current average P/E ratios for all sectors below)
ABUS Upcoming EarningsCurrently no data available.
ABUS Analysts Price TargetsCurrently no data available.
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of chronic hepatitis B (HBV) infections in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). Its lead candidate is ARB-1467, a multi-component RNAi therapeutic product that is designed for the elimination of HBV surface antigen expression in patients chronically infected with HBV. Its HBV product candidates also comprise ARB-1740, a RNAi HBV candidate that is in preclinical studies; small molecule cccDNA formation inhibitors for reducing the amount of cccDNA in the infected liver cell; HBV core protein assembly inhibitors; ARB-1598, a toll-like receptor; surface antigen secretion inhibitors; cccDNA epigenetic modifiers; stimulator of interferon genes agonists; and cyclophilin inhibitor drug candidates, including OCB-030 and other cyclophilin inhibitors. In addition, it develops TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials for the treatment of gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and hepatocellular carcinoma; TKM-HTG, a multi-component RNAi therapeutic that targets a combination of genes expressed in the liver, which play a role in triglyceride metabolism; and TKM-ALDH, an aldehyde dehydrogenase to induce long term acute sensitivity to ethanol to treat severe alcohol use disorder. Further, its partnered programs consists of ALN-TTR02,whichis in Phase III clinical study, a therapeutic targeting transthyretin mediated amyloidosis; ALN-VSP for liver cancer; ALN-PCS02 for hypercholesterolemia; Marqibo for treating Philadelphia chromosome-negative acute lymphoblastic leukemia; and DCR-PH1 for primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.
Last 3 Quarters for ABUS Premium
Below you can see how ABUS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Average Sector P/E ratio
Is your stock priced above or below the average P/E ratio?
A higher P/E ratio shows that investors are willing to pay a higher share price today because of growth expectations in the future. For example, a company with a current P/E of 25, trades at 25 times today's earnings.
|Name||Number of firms||Average PE|
|Auto & Truck||13||15|
|Bank (Money Center)||7||11|
|Brokerage & Investment Banking||39||14|
|Business & Consumer Services||165||32|
|Coal & Related Energy||22||7|
|Electronics (Consumer & Office)||20||18|
|Environmental & Waste Services||82||70|
|Financial Svcs. (Non-bank & Insurance)||232||36|
|Green & Renewable Energy||22||88|
|Healthcare Support Services||128||131|
|Heathcare Information and Technology||129||132|
|Investments & Asset Management||192||120|
|Metals & Mining||92||37|
|Office Equipment & Services||22||16|
|Oil/Gas (Production and Exploration)||269||19|
|Packaging & Container||24||43|
|Publishing & Newspapers||31||28|
|Real Estate (Development)||20||146|
|Real Estate (General/Diversified)||12||31|
|Real Estate (Operations & Services)||57||23|
|Retail (Building Supply)||17||202|
|Retail (Grocery and Food)||13||38|
|Retail (Special Lines)||89||25|
|Shipbuilding & Marine||10||30|
|Software (System & Application)||363||144|
|Total Market (without financials)||5878||62|
Updated: Jan 2020
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.